Dengue vaccines and Vaccination Status in Peru and Latin America: A narrative review

Authors

  • Carlos Quispe-Vicuña Red de Eficacia Clínica y Sanitaria (REDECS). Lima, Perú.
  • Julieta M. Araoz-Salinas Peruvian American Medical Society. Albuquerque, NM 87111, USA.
  • Brando Ortiz-Saavedra Universidad Nacional de San Agustín de Arequipa. Arequipa, Perú.
  • Jose A. Gonzales-Zamora Division of Infectious Diseases, Department of Medicine, Miller School of Medicine, University of Miami. Miami, FL 33136, USA.

DOI:

https://doi.org/10.15381/anales.v85i2.27783

Keywords:

Dengue, Vaccines, Peru, Latin America

Abstract

Due to the recent increase of dengue cases in Latin America, preventive measures beyond vector control or community participation are needed. In this regard, the use of vaccines has emerged as a promising tool. To date, there are three vaccines in phase III clinical trials: CYD-TDV, TAK-003 and Butantan-DV, all showing high efficacy and safety. Several Latin American countries have started implementing vaccination programs with TAK-003 (Qgenda®) vaccine since 2023. Brazil has initiated vaccination programs in children aged 10-14 years and Argentina has implemented TAK-003 vaccine in the private sector. In Peru, despite recent outbreaks of dengue, vaccination has not been considered in the national dengue plan. Although its incorporation represents a public health challenge, we believe that the vaccine would be useful in limiting severe cases and mortality from this disease.

Author Biographies

  • Carlos Quispe-Vicuña, Red de Eficacia Clínica y Sanitaria (REDECS). Lima, Perú.

    Physician.

  • Julieta M. Araoz-Salinas, Peruvian American Medical Society. Albuquerque, NM 87111, USA.

    Physician.

  • Brando Ortiz-Saavedra, Universidad Nacional de San Agustín de Arequipa. Arequipa, Perú.

    Physician.

  • Jose A. Gonzales-Zamora, Division of Infectious Diseases, Department of Medicine, Miller School of Medicine, University of Miami. Miami, FL 33136, USA.

    Infectious disease specialist.

Downloads

Published

2024-06-27

Issue

Vol. 85 No. 2 (2024)

Section

Artículo Especial

License

Copyright (c) 2024 Anales de la Facultad de Medicina

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

  1. Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
  2. Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
  3. Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

1.
Quispe-Vicuña C, Araoz-Salinas JM, Ortiz-Saavedra B, Gonzales-Zamora JA. Dengue vaccines and Vaccination Status in Peru and Latin America: A narrative review. An Fac med [Internet]. 2024 Jun. 27 [cited 2024 Jul. 17];85(2):211-6. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/27783